You searched for biotherapeutics

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis…

September 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies

VacV Biotherapeutics, a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its pipeline of pre-clinical assets with best-in-class potential, towards the clinic. VacV Biotherapeutics…

October 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Aug 2022

Aro Biotherapeutics gets FDA orphan drug designation for treatment of Pompe Disease

…to meaningful reductions in glycogen levels in the skeletal muscle in the Pompe mouse disease model. Aro Biotherapeutics anticipates entering clinical trials with ABX1100 in mid-2023. About Aro Biotherapeutics Based…

August 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Oxford BioTherapeutics enters into antibody agreement with Genmab

Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates…

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Neukio Biotherapeutics completes financing round for development of cell therapy products

Neukio Biotherapeutics, a Chinese company committed to developing novel cell therapy products, has closed $50 million in a series A-1 funding round. The investment round was led by CD Capital,…

September 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Aeglea BioTherapeutics updates homocystinuria program

Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria is under way. Patients in this cohort…

October 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June…

February 9, 2023 - 2 minutesmins - By Jim Cornall

accelerate biotherapeutics' path to clinic, next-generation biotherapeutics, biologics, Lonza

How to accelerate your biotherapeutics’ path to clinic

Over the last few decades, many novel biotherapeutics have undergone clinical trial testing in the quest to address unmet medical needs across various disease areas. However, the promise of breakthrough…

June 21, 2023 - 5 minutesmins - By Sudha Sundaram

News and Trends 16 Mar 2023

Inspire Biotherapeutics launches to target lung diseases through gene therapy

Inspire Biotherapeutics Inc., an emerging Canadian biotech company with a mission to create gene therapies for monogenic and acquired diseases of the lung, is set to move its novel lung…

March 16, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Kling Biotherapeutics doses first patient in advanced solid tumor trial

Kling Biotherapeutics BV has dosed the first patient with KBA1412 in its phase 1b trial to evaluate the safety, tolerability, PK/PD, and potential efficacy of KBA1412 in adult patients with…

September 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Aug 2022

Aeglea BioTherapeutics’ arginine 1 deficiency treatment gets EMA ok

…U.S. Food and Drug Administration as well as Orphan Drug Designation from the European Medicines Agency. About Aeglea BioTherapeutics Aeglea BioTherapeutics is a clinical-stage biotechnology company. It also has an…

August 19, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Jun 2022

TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies

TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and…

June 15, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: biotherapeutics

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies

Aro Biotherapeutics gets FDA orphan drug designation for treatment of Pompe Disease

Oxford BioTherapeutics enters into antibody agreement with Genmab

Neukio Biotherapeutics completes financing round for development of cell therapy products

Aeglea BioTherapeutics updates homocystinuria program

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

How to accelerate your biotherapeutics’ path to clinic

Inspire Biotherapeutics launches to target lung diseases through gene therapy

Kling Biotherapeutics doses first patient in advanced solid tumor trial

Aeglea BioTherapeutics’ arginine 1 deficiency treatment gets EMA ok

TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!